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Background: The efﬁcacy, safety, and tolerability of lisdexamfetamine dimesylate (LDX) augmentation of
antidepressant monotherapy in adults with major depressive disorder (MDD) from two phase 3 studies
are reported.
Methods: Across study 1 (placebo, n¼201; LDX, n¼201) and study 2 (placebo, n¼213; LDX, n¼211),
most participants (placebo and LDX) in the safety analysis set were female (study 1: 66.2% and 64.2%;
study 2: 67.1% and 66.8%); mean7SD ages were 41.8712.04 with placebo and 42.2712.32 with LDX in
study 1 and 42.6711.41 with placebo and 42.0711.63 with LDX in study 2. Participants (18–65 y) had
DSM-IV-TR–diagnosed MDD and lead-in baseline Montgomery-Åsberg Depression Rating Scale (MADRS)
total scores Z24. Eight-week antidepressant lead-in phases prospectively assessed antidepressant re-
sponse. Then, 8 weeks of randomized (1:1), double-blind treatment with dose-optimized LDX (20–
70 mg) or placebo in participants exhibiting inadequate antidepressant monotherapy responses (aug-
mentation baseline MADRS total scores Z18 and o50% MADRS total score reductions from lead-in
baseline to augmentation baseline) was initiated. The primary endpoint was MADRS total score change
from augmentation baseline to week 16. Safety and tolerability measures included the occurrence of
treatment-emergent adverse events (TEAEs).
Results: Least squares mean (95% CI) treatment differences (LDX–placebo) for MADRS total score changes
from augmentation baseline to week 16 were not statistically signiﬁcant in study 1 (0.1 [–1.7, 2.0],
P¼0.883) or study 2 (–0.5 [–2.3, 1.3], P¼0.583). The only TEAE reported by 45% of LDX participants at
twice the placebo rate in both studies was dry mouth.
Limitations: Limitations include the exclusion of participants with psychiatric comorbidities/active
medical disorders, the inability to assess speciﬁc MDD symptom domains (eg, anhedonia, cognition) or
subtypes, the use of telephone-based depression assessments, and the potential inﬂuence of placebo
response.
Conclusion: Contrary to expectations, LDX augmentation was not superior to placebo in reducingB.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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C. Richards et al. / Journal of Affective Disorders 206 (2016) 151–160152depressive symptoms in individuals with MDD exhibiting inadequate responses to antidepressant
monotherapy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Currently approved treatments for major depressive disorder
(MDD), including selective serotonin reuptake inhibitors (SSRIs)
and serotonin-norepinephrine reuptake inhibitors (SNRIs), effec-
tively reduce MDD symptoms (Arroll et al., 2005; Cipriani et al.,
2009). Nevertheless, more than half of patients with MDD do not
experience full remission with antidepressant monotherapy or
with augmentation therapy (Rush et al., 2006; Trivedi et al., 2006a,
2006b). For example, in the Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) study, low remission rates (27.5%
based on the 17-item Hamilton Depression Rating Scale, 32.9%
based on the 16-item Quick Inventory of Depressive Symptoma-
tology–Self-Report [QIDS-SR]) were observed with citalopram
monotherapy (Trivedi et al., 2006b). In addition, only 29.7% to
39.0% of individuals receiving second-step augmentation with
sustained-release bupropion or buspirone achieved remission
(Trivedi et al., 2006a).
Despite the relatively high partial remission rates following
antidepressant therapy, there are few medications approved by
the US Food and Drug Administration for use as augmentation
agents in MDD. Psychostimulants have been investigated for use as
augmentation agents in MDD since the 1950s (Robin and Wise-
berg, 1958). However, in 2 meta-analyses (Candy et al., 2008;
Fleurence et al., 2009), mixed results were reported with respect
to the efﬁcacy of psychostimulants or eugorics (modaﬁnil) as
augmentation therapy in MDD.
Lisdexamfetamine dimesylate (LDX) is approved in the United
States and in other countries for use in patients 6 years and older
with attention-deﬁcit/hyperactivity disorder (ADHD) and for use
in adults with moderate to severe binge eating disorder only in the
United States Vyvanse® [lisdexamfetamine dimesylate] 2015. The
efﬁcacy of LDX in MDD has been investigated in small, phase 2,
randomized, double-blind, placebo-controlled studies in in-
dividuals with MDD who exhibited inadequate response to anti-
depressant monotherapy (Madhoo et al., 2014; Trivedi et al., 2013).
In one study, LDX augmentation of escitalopram met signal-de-
tection criteria (prespeciﬁed 2-sided signiﬁcance level α¼0.10) for
signiﬁcant reduction in mean Montgomery-Åsberg Depression
Rating Scale (MADRS) total score versus placebo in escitalopram
nonremitters (Trivedi et al., 2013). In a separate study that focused
on treating executive dysfunction in individuals with fully or
partially remitted MDD (deﬁned as MADRS total scores r18), LDX
augmentation of SSRI monotherapy produced signiﬁcantly greater
reductions in MADRS total score than placebo (Madhoo et al.,
2014).
This report presents the ﬁndings of two phase 3 studies de-
signed to assess the efﬁcacy, safety, and tolerability of LDX aug-
mentation in adults with MDD who exhibit inadequate response
to an 8-week prospective course of antidepressant therapy. The
primary objective of each study was to assess the efﬁcacy of LDX
augmentation, as measured by change in MADRS total score.
Secondary objectives included assessment of LDX augmentation
effects on the Sheehan Disability Scale (SDS; the key secondary
endpoint), on other secondary efﬁcacy endpoints, and on safety
and tolerability.2. Methods
2.1. Study design and treatment regimens
Study 1 (ClinicalTrials.gov identiﬁer: NCT01436149) was con-
ducted at 76 sites across Canada, Croatia, Mexico, Spain, and the
United States. Study 2 (ClinicalTrials.gov identiﬁer: NCT01436162)
was conducted at 94 sites across the Czech Republic, Estonia,
Finland, Germany, Hungary, Poland, Romania, South Africa, Swe-
den, and the United States. Both studies were conducted in ac-
cordance with guidelines from the International Conference on
Harmonization Good Clinical Practice and the principles of the
Declaration of Helsinki. All study protocols were approved by
ethics committees and regulatory agencies before initiating the
studies, and written informed consent was obtained before per-
forming study-related procedures.
Each study employed a multicenter, randomized, double-blind,
parallel-group, placebo-controlled, ﬂexible-dose design. With the
exception of differences in some of the secondary endpoints, the
studies were identically designed and consisted of 4 phases
(Fig. 1): a screening period of 1–4 weeks, an 8-week anti-
depressant lead-in phase (to prospectively conﬁrm inadequate
response to antidepressant monotherapy), an 8-week double-
blind treatment phase (3 weeks of dose optimization followed by
5 weeks of dose maintenance), and a 7- to 9-day follow-up period.
After screening, eligible participants entered the 8-week sin-
gle-blind antidepressant lead-in phase, which prospectively as-
sessed response to antidepressant monotherapy and blinded par-
ticipants to the time of randomization. During the antidepressant
lead-in phase, participants were assigned by investigators to 1 of
4 commercially available antidepressant medications: an SSRI
(escitalopram oxalate [10 or 20 mg] or sertraline hydrochloride
[50–200 mg]) or an SNRI (venlafaxine hydrochloride extended
release [37.5–375 mg] or duloxetine hydrochloride [30–120 mg]).
Antidepressant assignment was unblinded to both investigators
and participants and was based on clinical factors, including prior
antidepressant use, response, and tolerability. Each individual in-
vestigator was asked to distribute antidepressant treatments
equally at their site, attempting to not assign any 1 antidepressant
to 440% of participants. Investigators managed antidepressant
distribution at the site level and the study sponsor provided on-
going internal review of the overall distribution. No action from
the sponsor was taken to ensure that the protocol-stated anti-
depressant distribution was attained. The initial antidepressant
dose was taken after the lead-in baseline visit (week 0), with
treatment titrated to the maximum tolerated approved dose by
week 4; dose adjustments were not permitted after week 4.
Weekly dose increases were made by the investigator according to
product label guidelines. Antidepressant strength and doses varied
based on commercial availability and country and were adminis-
tered according to local guidelines. All participants also received
LDX-matched placebo during this phase.
Following the lead-in phase, participants exhibiting an in-
adequate response to antidepressant monotherapy entered the
double-blind treatment phase and were randomized (1:1) to LDX
or placebo. Randomization criteria included having a MADRS total
score of Z18 at augmentation baseline (week 8), having a MADRS
total score reduction of o50% from lead-in baseline to augmen-
tation baseline, exhibiting improvement in depressive symptoms
Fig. 1. Study designs for randomized participants (A) and non-randomized participants (B). LDX¼ lisdexamfetamine; V¼visit; Wk¼week.
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measured by MADRS total score, and having no changes since
lead-in baseline in physical examination, clinical laboratories,
electrocardiograms (ECGs), or vital signs that preclude LDX treat-
ment. Participants whose depressive symptoms improved but who
did not meet randomization criteria were not randomized (non-
randomized participants); these participants continued on a
modiﬁed schedule (visit 10 [week 10], 12 [week 12], and 14 [week
16]) and received single-blind placebo. Participants whose de-
pressive symptoms did not improve or worsened (based on
MADRS total score) on their assigned antidepressant were dis-
continued because LDX was not being assessed for efﬁcacy as
monotherapy and continuing a treatment with no demonstrated
efﬁcacy for the background antidepressant was considered to have
an unfavorable risk/beneﬁt balance. An interactive voice/web re-
sponse system was used to generate a randomization number,
stratiﬁed by sex and antidepressant type (SSRI vs SNRI), at aug-
mentation baseline.
The double-blind treatment phase consisted of 3 weeks of dose
optimization (weeks 8–11) followed by 5 weeks of dose main-
tenance (weeks 11–16). Study drug was taken each morning
(7:00 a.m. [72 h]); antidepressant treatment schedules were
maintained from the lead-in phase. To maintain blinding, LDX
capsules were over-encapsulated and appeared identical to pla-
cebo. During dose optimization, treatment was initiated with
30 mg LDX (or placebo). During weeks 9 and 10, the LDX dosage
could be maintained, increased to 50 or 70 mg, or down-titrated to
20 mg (Fig. 1). Dosage could be reduced once by a single dose level
at any time during dose optimization. Once reduced, the dosage
was maintained for the remainder of the study. During dose
maintenance, the dose being taken at week 11 was maintained
until week 16 unless there was an emergent safety concern, in
which case a single dose reduction was permitted. A vital signs
assessment was to be taken at the time of this dose reduction. All
participants returned for a safety follow-up visit approximately
7 to 9 days after the last study drug dose.2.2. Study populations
Both studies enrolled adult (18 [or age of majority if 418 y by
local regulation]-65 y at the time of consent) males or non-
pregnant females. Eligible participants were also required to have
a primary nonpsychotic MDD diagnosis (single or recurrent), as
deﬁned by the Structured Clinical Interview for Diagnostic and Sta-
tistical Manual for Mental Disorders, Fourth Edition–Text Revision,
Clinical Trial Version (SCID-CT), that had lasted for Z8 weeks be-
fore screening and to have a MADRS total score of Z24 at lead-in
baseline.
Participants were excluded if they had a current MDD episode
and did not sufﬁciently respond to adequate treatment (Z6 weeks
at the maximum tolerated dose) with Z2 approved anti-
depressants or to an approved augmentation therapy; a lifetime
history of treatment-resistant depression, deﬁned as unresponsive
to adequate treatment (Z8 weeks at the maximum tolerated
dose) with Z2 treatments, including distinct classes of approved
antidepressant monotherapy and adjunctive treatment; had been
hospitalized within the past 12 months for the current MDD epi-
sode; had current comorbid psychiatric disorders (any signiﬁcant
Axis II disorder, ADHD, bipolar disorder, current or lifetime psy-
chosis, posttraumatic stress disorder, obsessive compulsive dis-
order, pervasive development disorder, anorexia nervosa, bulimia
nervosa) established by the SCID-CT and controlled with pro-
hibited medications or uncontrolled and associated with sig-
niﬁcant symptoms; had symptoms (eg, agitated states) that con-
traindicated LDX treatment or could confound study assessments;
or had a ﬁrst-degree relative with bipolar I disorder (to ensure
depressive symptoms were not related to undiagnosed bipolar
disorder in a participant who had not yet experienced a manic
episode).
Additional exclusion criteria included suspected substance
abuse or dependence (except nicotine) within the past 6 months;
considered a suicide risk in the opinion of the investigator, had
made a suicide attempt within the past 3 years, or currently de-
monstrating active suicidal ideation; a history of symptomatic
cardiovascular disease or other cardiovascular medical conditions;
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pressure (SBP)4139 mmHg or diastolic blood pressure
(DBP)489 mmHg or a body mass index (BMI) of o18.5 or 440 at
screening or lead-in baseline; current use (within 30 days of
screening) of any centrally acting medication that could affect the
condition being studied or affect the action, absorption, or dis-
position of LDX; or participation in an LDX clinical trial or previous
use of commercially available LDX.
2.3. Study endpoints
2.3.1. Efﬁcacy
The primary efﬁcacy endpoint was MADRS total score change
from augmentation baseline to week 16. On the 10-item, clinician-
rated MADRS (Montgomery and Asberg, 1979) each item is scored
on a 7-point scale (0–6; higher scores indicate more severe
symptoms). The MADRS was assessed at screening, antidepressant
lead-in baseline (week 0), week 6, and augmentation baseline
(week 8) for all participants; and at all double-blind treatment
visits (weeks 8 through 16) for randomized participants. Although
all participants visited the study site for each visit, the MADRS was
completed by a central rater via telephone (MedAvante, Inc; Ha-
milton, NJ) who was blinded to study visit and entry criteria.
The prespeciﬁed key secondary endpoint was SDS total score
change from augmentation baseline to week 16. The SDS (Sheehan
et al., 1996) measures impairment of work/school, social life/lei-
sure activity, and family life/home responsibilities on scales ran-
ging from 0 to 10 (higher scores indicate more impairment; total
score range: 0–30). The SDS was assessed at antidepressant lead-in
baseline and augmentation baseline all participants and at all
double-blind treatment visits (weeks 8 through 16/end of study
[EOS]) for randomized participants.
Other secondary efﬁcacy endpoints were the Clinical Global
Impressions-Improvement (CGI-I) scale (Guy, 1976), the QIDS-SR
(study 1 only) (Rush et al., 2003), the global fatigue index of the
Multidimensional Assessment of Fatigue (MAF-GFI; study 2 only)
scale (Basia, 2014), and the Abbreviated Brief Assessment of Cog-
nition in Affective Disorders (ABAC-A; study 2 only), also referred
to as the Brief Assessment of Cognition in Schizophrenia (Kaneda
and Keefe, 2015). In both studies, CGI-I was assessed at all post-
antidepressant lead-in baseline visits. The QIDS-SR (study 1 only),
MAF (study 2 only), and the ABAC-A (study 2 only) were assessed
at lead-in baseline, augmentation baseline, and week 16/EOS.
2.3.2. Safety and tolerability
Safety and tolerability included examination of adverse events
(AEs), vital signs, clinical laboratory and ECG results, and responses
on the Columbia-Suicide Severity Rating Scale (C-SSRS) and the
Amphetamine Cessation Symptom Assessment (ACSA) scale. AEs
were assessed at all visits from the time of informed consent
through follow-up and were categorized based on severity, ser-
iousness, and relatedness to treatment; treatment-emergent AEs
(TEAEs) were deﬁned as AEs that began or deteriorated on or after
the date of the ﬁrst randomized treatment dose and no later than
3 days after the ﬁnal randomized treatment dose. Clinical labora-
tory tests were assessed at screening, lead-in and augmentation
baselines, week 12, and week 16/EOS. Vital signs and weight were
assessed at screening and all study visits through follow-up.
Twelve-lead ECGs were recorded at screening, lead-in and aug-
mentation baselines, and at week 16/EOS. The ACSA, a self-com-
pleted scale assessing amphetamine-related withdrawal symp-
toms (McGregor et al., 2008), was completed at follow-up. The
C-SSRS, a semistructured interview measuring the occurrence,
severity, and frequency of suicide-related thoughts and behaviors
(Posner et al., 2009), was assessed at screening, all study visits, and
follow-up.2.4. Statistical analyses
Sample sizes in both studies were based on the primary efﬁcacy
endpoint (MADRS total score change from the augmentation
baseline to week 16). Assuming a 3-point mean between-group
difference (SD¼8.1), it was estimated that 155 participants per
treatment would provide 90% power (2-sided 5% signiﬁcance le-
vel). Based on an estimated 20% discontinuation rate during the
double-blind treatment phase, approximately 388 participants
(194 per treatment) were to be randomized.
MADRS total score change in randomized participants was as-
sessed in the full analysis set (FAS: all participants taking Z1
randomized study drug dose and having Z1 post-augmentation
baseline MADRS assessment). The primary efﬁcacy analysis was
conducted using a mixed-effects model for repeated measures
(MMRM) analysis with treatment, visit, the treatment-by-visit
interaction, sex, and antidepressant class included as factors, and
augmentation baseline score as a covariate; the interaction of
augmentation baseline score with visit was adjusted for in the
model. Hypothesis testing was performed at the 2-sided 0.05 level
of signiﬁcance. Analysis of SDS total score change (the key sec-
ondary endpoint) was conducted using the same MMRM model
described for the primary efﬁcacy endpoint. The between-treat-
ment comparisons at week 16 were of main interest for both the
primary and key secondary endpoints.
Additional secondary efﬁcacy endpoints were also assessed at
week 16/EOS in the FAS. Percentages of participants demonstrat-
ing MADRS total score reductions from augmentation baseline of
25% or 50% and the percentage of participants achieving MADRS
remission (deﬁned by a MADRS total score r10) were assessed
using Cochran-Mantel-Haenszel (CMH) tests stratiﬁed by sex and
antidepressant class. Scores on the CGI-I were dichotomized as
improved (very much improved or much improved) or not im-
proved (minimally improved through very much worse) and as-
sessed using CMH tests stratiﬁed by sex and antidepressant class.
Changes from augmentation baseline for QIDS-SR total score
(study 1 only), ABAC-A composite T-scores (study 2 only), and the
MAF-GFI were assessed using an analysis of covariance model that
included treatment, sex, and antidepressant class as factors and
augmentation baseline score as a covariate.
Safety and tolerability were assessed in the safety analysis set,
which included all randomized participants taking Z1 rando-
mized study drug dose and having Z1 safety assessment during
double-blind treatment. All safety and tolerability endpoints are
presented using descriptive statistics.3. Results
3.1. Participant disposition and demographics
Participant disposition and participant demographics and
clinical characteristics are summarized in Fig. 2 and Table 1, re-
spectively. Across studies, most randomized participants were fe-
male and were white (Table 1). Higher percentages of participants
were assigned to SSRIs than SNRIs (Table 1). The most commonly
assigned agent was escitalopram; the distribution of ﬁnal lead-in
antidepressant doses is summarized in Table 1. Mean7SD MADRS
total scores at antidepressant lead-in baseline and at augmenta-
tion baseline were comparable between treatment groups in both
studies.
3.2. Prior MDD medication use
Before participation in the current studies, use of an MDD
medication was captured in the safety analysis set prior to
Fig. 2. Participant disposition. DBP¼diastolic blood pressure; ECG¼electrocardiogram; LDX¼ lisdexamfetamine dimesylate; MADRS¼Montgomery-Åsberg Depression
Rating Scale; SBP¼systolic blood pressure. *Participants could have had multiple reasons for not being randomized to double-blind treatment. †Sustained elevations in
average (of 3 readings) sitting SBP (an increase of Z10 mmHg from lead-in baseline and an average value Z140 mmHg on 2 consecutive visits), or sitting DBP (an increase
of Z10 mmHg from lead-in baseline and an average value Z90 mmHg on 2 consecutive visits), or pulse rate (an increase of Z20 bpm from lead-in baseline and an average
value Z100 bpm on 2 consecutive visits).
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the assigned background antidepressant in the current studies).
Prior MDD medication use was reported by 57.0% (229/402) and
64.2% (272/424) of participants in studies 1 and 2, respectively.
The most frequently used MDD medications (Z5% of participants)
were escitalopram (16.4% [66/402]), sertraline (13.2% [53/402]),
duloxetine (12.4% [50/402]), ﬂuoxetine (11.7% [47/402]), citalo-
pram (11.4% [46/402]), bupropion (10.9% [44/402]), paroxetine
(9.0% [36/402]), and venlafaxine (7.7% [31/402]) in study 1 and
citalopram (18.9% [80/424]), sertraline (18.6% [79/424]), venlafax-
ine (17.7% [75/424]), escitalopram (16.0% [68/424]), ﬂuoxetine
(11.6% [49/424]), bupropion (8.0% [34/424]), paroxetine (8.0% [34/
424]), duloxetine (7.8% [33/424]), and any investigational drug
(5.9% [25/424]) in study 2.
3.3. Extent of exposure and treatment compliance
During double-blind treatment, mean7SD exposure days for
placebo and LDX, respectively, were 49.5715.54 and 50.1714.76
in study 1 and 52.5712.33 and 51.5713.17 in study 2. During the
double-blind treatment periods in studies 1 and 2, respectively,
74.1% (149/201) and 62.6% (132/211) of participants had their LDX
dose increased to 50 mg and 39.3% (79/201) and 33.6% (71/211)
had their dose increased to 70 mg; 6.0% (12/201) and 9.5% (20/211)
had their dose down-titrated to 20 mg. The mean7SD daily LDX
dose during double-blind treatment was 46.5713.74 mg in study
1 and 43.4714.35 mg in study 2. Most participants (study 1
[placebo: 88.1% (177/201), LDX: 91.5% (184/201)]; study 2 [placebo:96.2% (205/213), LDX: 98.1% (207/211)]) had compliance rates
(deﬁned as [total number of capsules taken100]/total planned
days of dosing) in the range of 80% to 120%.
3.4. Efﬁcacy
3.4.1. Primary endpoint – change in MADRS total score
In both studies, least squares (LS) mean MADRS total score
decreases from augmentation baseline to week 16 were observed
with placebo and LDX (Fig. 3). As reported in Table 2, the between-
treatment difference (LDX – placebo) for mean change from aug-
mentation baseline to week 16 in MADRS total score in the entire
FAS was not statistically signiﬁcant in either study (both P40.05).
Findings were similar when assessed by sex or antidepressant
class (Supplemental Fig. 1).
3.4.2. Secondary efﬁcacy endpoints
Findings for the SDS (key secondary endpoint) and other sec-
ondary efﬁcacy endpoints are presented in Table 2. In both studies,
there were no statistically signiﬁcant or clinically meaningful
treatment differences for the change from augmentation baseline
to week 16 between placebo and LDX for SDS total score (Table 2)
or for the individual SDS domain scores (data not shown). Across
most of the other secondary efﬁcacy endpoints (dichotomized CGI-
I, QIDS-SR, ABAC-A, MADRS remission rate, MADRS 50% response
rate) similar ﬁndings were observed, with few nominally statisti-
cally signiﬁcant treatment effects being observed between placebo
and LDX at week 16/EOS (Table 2). However, because the primary
Table 1
Demographic and baseline clinical characteristics, safety analysis set.
Study 1 Study 2
Placebo (n¼201) LDX (n¼201) Placebo (n¼213) LDX (n¼211)
Mean7SD age, years 41.8712.04 42.2712.32 42.6711.41 42.0711.63
Sex, n (%)
Male 68 (33.8) 72 (35.8) 70 (32.9) 70 (33.2)
Female 133 (66.2) 129 (64.2) 143 (67.1) 141 (66.8)
Race, n (%)
White 160 (79.6) 154 (76.6) 183 (85.9) 174 (82.5)
Black/African American 36 (17.9) 39 (19.4) 24 (11.3) 34 (16.1)
Native Hawaiian/Paciﬁc Islander 0 0 1 (0.5) 1 (0.5)
Asian 5 (2.5) 5 (2.5) 3 (1.4) 1 (0.5)
American Indian/Alaska Native 0 1 (0.5) 0 0
Other 0 2 (1.0) 2 (0.9) 1 (0.5)
Mean7SD weight, kg 82.4717.90 81.3718.34 80.8718.52 82.2717.66
Mean7SD body mass index, kg/m2 28.975.43 28.575.66 28.175.47 28.475.45
Mean7SD MADRS total score
Lead-in baseline 33.274.63 33.875.01 34.175.21 33.474.39
Augmentation baseline 25.275.03 25.474.75 25.775.29 26.075.15
Mean7SD SDS scores at augmentation baselinea
Total score 15.675.65 15.975.99 16.875.75 16.875.34
Disrupted family life score 5.272.05 5.272.19 5.572.18 5.671.98
Disrupted social life score 5.672.16 5.772.09 5.872.14 5.871.95
Disrupted work/school score 4.772.26 5.072.36 5.572.23 5.372.27
Lead-in baseline antidepressant, n (%)
Venlafaxine HCl extended-release (SNRI) 25 (12.4) 21 (10.4) 52 (24.4) 48 (22.7)
Duloxetine HCl (SNRI) 62 (30.8) 65 (32.3) 46 (21.6) 48 (22.7)
Escitalopram oxalate (SSRI) 67 (33.3) 80 (39.8) 66 (31.0) 63 (29.9)
Sertraline HCl (SSRI) 47 (23.4) 35 (17.4) 49 (23.0) 52 (24.6)
Final antidepressant dose, n (%)
Venlafaxine HCl extended-release (SNRI)
37.5 mg 1 (0.5) 0 – –
75 mg 0 1 (0.5) 7 (3.3) 7 (3.3)
150 mg 3 (1.5) 4 (2.0) 18 (8.5) 17 (8.1)
225 mg 21 (10.4) 16 (8.0) 22 (10.3) 20 (9.5)
300 mg – – 3 (1.4) 3 (1.4)
375 mg – – 2 (0.9) 1 (0.5)
Duloxetine HCl (SNRI)
30 mg 1 (0.5) 2 (1.0) 0 2 (0.9)
40 mg 5 (2.5) 5 (2.5) 1 (0.5) 1 (0.5)
60 mg 48 (23.9) 44 (21.9) 31 (14.6) 37 (17.5)
90 mg 3 (1.5) 6 (3.0) 3 (1.4) 2 (0.9)
120 mg 5 (2.5) 8 (4.0) 11 (5.2) 6 (2.8)
Escitalopram oxalate (SSRI)
10 mg 7 (3.5) 13 (6.5) 12 (5.6) 11 (5.2)
20 mg 60 (29.9) 67 (33.3) 54 (25.4) 52 (24.6)
Sertraline HCl (SSRI)
50 mg 3 (1.5) 2 (1.0) 4 (1.9) 8 (3.8)
100 mg 8 (4.0) 7 (3.5) 13 (6.1) 18 (8.5)
150 mg 14 (7.0) 12 (6.0) 4 (1.9) 15 (7.1)
200 mg 22 (10.9) 14 (7.0) 28 (13.1) 11 (5.2)
LDX¼ lisdexamfetamine dimesylate; MADRS¼Montgomery-Åsberg Depression Rating Scale; SDS¼Sheehan Disability Scale; SNRI¼serotonin-norepinephrine reuptake in-
hibitor; SSRI¼selective serotonin reuptake inhibitor.
a Based on Full Analysis set: study 1 (total score [placebo, n¼198; LDX, n¼198], disrupted family life score [placebo, n¼199; LDX, n¼199], disrupted social life score
[placebo, n¼199; LDX, n¼198], disrupted work/school score [placebo, n¼198; LDX, n¼199]); study 2 (placebo, n¼213; LDX, n¼209).
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in secondary endpoints should not be considered statistically
signiﬁcant.
3.5. Safety and tolerability
3.5.1. Adverse events
Treatment-emergent AE (TEAEs) are summarized in Table 3. In
both studies, higher percentages of TEAEs were reported with LDX
than with placebo. Most TEAEs were mild or moderate in in-
tensity; the frequency of severe TEAEs was low in both studies (see
footnote to Table 3 for a complete listing). TEAEs leading to dis-
continuation were generally of mild to moderate intensity in both
studies (see footnote to Table 3 for a complete listing of TEAEs
leading to discontinuation), with the exception of 2 cases in study1 (syncope in an LDX participant; suicide attempt in a placebo
participant; both resolved) and 2 cases in study 2 (anxiety in an
LDX participant; suicidal ideation in a placebo participant). The
most frequently occurring TEAEs are summarized in Table 3. The
TEAEs reported by Z5% of participants treated with LDX and at
twice the rate of placebo were dry mouth and nasopharyngitis in
study 1 and dry mouth and decreased appetite in study 2. There
were no instances of psychosis/mania or aggression reported as
TEAEs or deaths in either study.
Few serious TEAEs were reported in either study (Table 3). In
study 1, there were 3 serious TEAEs in the LDX group (nonsuicidal
overdose of diphenhydramine, syncope, and appendicitis; none
were considered treatment related by the investigator) and 7 ser-
ious TEAEs in the placebo group (suicide attempt, major depres-
sion, vertigo, syncope, appendectomy, laceration, and skin
Fig. 3. Change in MADRS total score during double-blind treatment (full analysis
set) for Study 1 (A) and Study 2 (B). LDX¼ lisdexamfetamine; dimesylate
MADRS¼Montgomery-Åsberg Depression Rating Scale.
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considered to be treatment related by the investigator. In study 2,
the 2 serious TEAEs (suicidal ideation in a placebo participant and
accelerated hypertension in an LDX participant) were both con-
sidered related to treatment; the suicidal ideation event resulted
in study withdrawal but the case of accelerated hypertension did
not.
3.5.2. Vital signs and electrocardiogram
At week 16/EOS, mean SBP and DBP decreased with placebo
and increased with LDX in study 1. In study 2, increases in SBP and
DBP at week 16/EOS were numerically larger with LDX than with
placebo (Table 3). In both studies, mean increases in pulse with
LDX were numerically larger than those observed for placebo
(Table 3). The proportion of participants with potentially clinically
important changes in SBP, DBP, and pulse was generally higher
with LDX than with placebo (Table 3). Based on the ECG, mean
heart rate increases and QT duration decreases were numerically
larger with LDX than with placebo in both studies (Table 3). Fri-
dericia-corrected QT interval decreases were comparable with
placebo and LDX in study 1, but were numerically larger with LDX
in study 2.
3.5.3. Other safety and tolerability endpoints
Mean weight and BMI increased with placebo and decreased
with LDX in both studies (Table 3). Six LDX-treated participants
(3.0%) in study 1 and 8 LDX-treated participants (3.8%) in study
2 exhibited Z7% decreases in body weight from the augmentation
baseline; no placebo participants met this criterion in either study.
Four placebo-treated participants (2.0%) in study 1 and 2 placebo-treated participants (0.9%) in study 2 had a Z7% increase in body
weight from the augmentation baseline; no LDX participants met
this criterion in either study. There were no differences of clinical
concern between treatment groups regarding clinical laboratory
ﬁndings in either study.
On the C-SSRS, Z1 positive suicidal ideation occurred during
double-blind treatment in 14 placebo (7.0%) and 14 LDX (7.0%)
participants in study 1 and in 20 placebo (9.4%) and 19 LDX (9.0%)
participants in study 2. At least 1 suicide attempt was reported on
the C-SSRS during double-blind treatment in 1 (0.5%) placebo
participant in each study; the suicide attempt in study 2 was also
recorded as a TEAE of mild intensity.
At follow-up, mean7SD ACSA total scores were 15.1710.71
with placebo (n¼178) and 14.7710.94 with LDX (n¼183) in study
1 and 17.2710.56 with placebo (n¼199) and 17.0710.80 (n¼194)
with LDX in study 2.4. Discussion
The primary ﬁnding of the current studies was that augmen-
tation of antidepressant therapy with LDX was not associated with
signiﬁcantly different reductions in MADRS total score (the pri-
mary efﬁcacy endpoint) than placebo augmentation in adults with
inadequate responses to 8 weeks of standard antidepressant
therapy. Similar ﬁndings were observed for the prespeciﬁed key
secondary endpoint (SDS total score) and the other secondary ef-
ﬁcacy endpoints.
These ﬁndings do not support previously published ﬁndings of
LDX augmentation for MDD based on 2 small phase 2 studies
(Madhoo et al., 2014; Trivedi et al., 2013), but they are generally
consistent with published ﬁndings for psychostimulant (Patkar
et al., 2006; Postolache et al., 1999; Ravindran et al., 2008) and
modaﬁnil augmentation studies for MDD (DeBattista et al., 2003;
Dunlop et al., 2007; Fava et al., 2007) and with the conclusions of
published meta-analyses (Candy et al., 2008; Fleurence et al.,
2009). Discrepancies between the current phase 3 studies and
previously published phase 2 studies might be attributed to study
design differences. The phase 3 studies required that participants
have MADRS total scores of Z18 at augmentation baseline and
MADRS total score reductions of o50% from the antidepressant
lead-in baseline to augmentation baseline, but the phase 2 studies
included participants with 17-item Hamilton Depression Rating
Scale scores Z4 (Trivedi et al., 2013) or with executive dysfunction
and MADRS total scores r18 (Madhoo et al., 2014). Second, both
phase 2 studies included smaller study populations and used only
SSRIs as the antidepressant medication (Madhoo et al., 2014; Tri-
vedi et al., 2013). It has been suggested that using small, under-
powered, proof-of-concept studies in the design of larger, rando-
mized clinical trials may be problematic (Kraemer and Kupfer,
2006). Despite these potential explanations, it is important to note
that the phase 3 studies described in this report were more rig-
orously designed and better powered than the published phase
2 studies (Madhoo et al., 2014; Trivedi et al., 2013). As such, these
ﬁndings indicate that LDX was not superior to placebo in reducing
the depressive symptoms of MDD.
The lack of efﬁcacy observed in the current study may indicate
that psychostimulants as a class are ineffective in treating un-
differentiated residual depressive symptoms in individuals who
exhibit an inadequate response to antidepressant monotherapy.
Alternatively, it is possible that clinician-rated scales, such as
MADRS, do not capture the true effects of psychostimulants or that
psychostimulants do not provide multidimensional symptom re-
lief. Rather, they may provide dimensional efﬁcacy for individuals
with symptoms related to anhedonia, fatigue, or cognitive dys-
function. The possibility that the failure to observe an effect of LDX
Table 2
Efﬁcacy assessments at end of double-blind treatment, full analysis set.
Study 1 Study 2
Placebo LDX Placebo LDX
MADRS total score (primary endpoint)a
Mean7SD total score at augmentation baseline 25.275.03 25.474.77 25.775.29 26.075.16
Mean7SD total score at week 16 18.979.99 19.179.10 18.978.85 18.379.58
LS mean (95% CI) change from augmentation baseline at week 16 6.3 (7.6, 4.9) 6.1 (7.5, 4.8) 6.8 (8.1, 5.5) 7.3 (8.6, 6.0)
LS mean (95% CI) treatment difference at week 16 0.1 (1.7, 2.0); Po0.883 0.5 (2.3, 1.3); Po0.583
SDS total score (key secondary endpoint)b
Mean7SD total score at augmentation baseline 15.675.65 15.975.99 16.875.75 16.875.34
Mean7SD total score at week 16 11.577.30 11.076.86 12.177.03 11.477.23
LS mean (95% CI) change from augmentation baseline at week 16 4.3 (5.3, 3.3) 4.7 (5.6, 3.7) 4.3 (5.2, 3.4) 4.9 (5.8, 4.0)
LS mean (95% CI) treatment difference at week 16 0.4 (1.8, 1.0); P¼0.576 0.6 (1.9, 0.7); P¼0.354
MAF-GFI (secondary endpoint)c
Mean7SD total score at augmentation baseline – – 32.379.36 32.678.77
Mean7SD total score at week 16 – – 27.8711.78 25.6711.16
LS mean (95% CI) change from augmentation baseline at week 16 – – 4.4 (5.8, 3.0) 6.6 (8.0, 5.1)
LS mean (95% CI) treatment difference at week 16 – 2.2 (4.1, 0.2); nominal P¼0.031
QIDS-SR total score (secondary endpoint)d
Mean7SD total score at augmentation baseline 11.973.74 11.873.97 – –
Mean7SD total score at week 16 9.674.66 9.674.79 – –
LS mean (95% CI) change from augmentation baseline at week 16 2.6 (3.2, 1.9) 2.3 (2.9, 1.7) – –
LS mean (95% CI) treatment difference at week 16 0.3 (0.6, 1.1); nominal P¼0.500 –
ABAC-A T-composite score (secondary endpoint)e
Mean7SD total score at augmentation baseline – – 46.1713.18 45.0713.35
Mean7SD total score at week 16 – – 48.2712.96 47.7712.70
LS mean (95% CI) change from augmentation baseline at week 16 – – 2.5 (1.5, 3.5) 3.0 (2.1, 4.0)
LS mean (95% CI) treatment difference at week 16 – 0.5 (0.8, 1.9); nominal P¼0.435
25% MADRS response at week 16/EOS (secondary endpoint)
n/N (%) 130/200 (65.0) 149/200 (74.5) 158/213 (74.2) 144/209 (68.9)
Nominal P value 0.039 0.234
50% MADRS response at week 16/EOS (secondary endpoint)
n/N (%) 77/200 (38.5) 82/200 (41.0) 79/213 (37.1) 87/209 (41.6)
Nominal P value 0.591 0.342
MADRS remission at week 16/EOS (secondary endpoint)
n/N (%) 45/200 (22.5) 37/200 (18.5) 38/213 (17.8) 48/209 (23.0)
Nominal P value 0.335 0.195
CGI-I Improved at week 16/EOS (secondary endpoint)
n/N (%) 106/199 (53.3) 110/199 (55.3) 114/213 (53.5) 119/209 (56.9)
Nominal P value 0.729 0.486
ABAC-A¼Abbreviated Brief Assessment of Cognition in Affective Disorders; CGI-I¼Clinical Global Impressions-Improvement; EOS¼end of study; MADRS¼Montgomery-
Åsberg Depression Rating Scale; MAF-GFI=global fatigue index of the Multidimensional Assessment of Fatigue; QIDS-SR=Quick Inventory of Depressive Symptomatology–
Self-Report; SDS¼Sheehan Disability Scale.
a MADRS sample sizes: augmentation baseline (study 1 [placebo (n¼200), LDX (n¼200)]; study 2 [placebo (n¼213), LDX (n¼209)]); week 16, LS mean change from
augmentation baseline, and LS mean treatment difference at week 16 (study 1 [placebo (n¼165), LDX (n¼163)]; study 2 [placebo (n¼189), LDX (n¼181)]).
b SDS sample sizes: augmentation baseline (study 1 [placebo (n¼198), LDX (n¼198)]; study 2 [placebo (n¼213), LDX (n¼209)]); week 16 (study 1 [placebo (n¼165),
LDX (n¼163)]; study 2 [placebo (n¼189), LDX (n¼180)]); LS mean change from augmentation baseline and LS mean treatment difference at week 16 (study 1 [placebo
(n¼164), LDX (n¼162)]), study 2 (placebo [n¼189], LDX [n¼180]).
c MAF-GFI sample sizes: augmentation baseline (study 2 [placebo (n¼212), LDX (n¼209)]); week 16, LS mean change from augmentation baseline and LS mean
treatment difference at week 16 (study 2 [placebo (n¼205), LDX (n¼197)]).
d QIDS-SR sample sizes: augmentation baseline (study 1 [placebo (n¼197), LDX (n¼199)]); week 16 (study 1 [placebo (n¼189), LDX (n¼186)]); LS mean change from
augmentation baseline and LS mean treatment difference at week 16 (study 1 [placebo (n¼186), LDX (n¼185)]).
e ABAC-A sample sizes: augmentation baseline (study 2 [placebo (n¼213), LDX (n¼209)]); week 16, LS mean change from augmentation baseline and LS mean
treatment difference at week 16 (study 2 [placebo (n¼198), LDX (n¼194)]).
C. Richards et al. / Journal of Affective Disorders 206 (2016) 151–160158was related to the use of the MADRS seems unlikely because of the
consistent lack of effect observed across all study assessments,
including the QIDS-SR. In support of the latter hypothesis, me-
thylphenidate has been reported to be efﬁcacious in reducing
apathy in individuals with Alzheimer's disease (Rosenberg et al.,
2013) and apathy and fatigue in individuals with MDD (Ravindran
et al., 2008). Additionally, a previously published study reported
LDX augmentation signiﬁcantly improved self-reported and in-
formant-reported executive dysfunction, as measured by the Be-
havior Rating Inventory of Executive Function-Adult Version, in
participants with mild MDD (Madhoo et al., 2014). However, given
the lack of effect of LDX on the ABAC-A in the current studies, this
ﬁnding also needs to be cautiously considered. Nevertheless, the
possibility that psychostimulants may effectively reduce apathy,
inattention, or indifference (symptoms that may not be effectively
captured by the MADRS or ABAC-A) remains. Additional studiesare needed to understand the nuanced effects of psychostimulants
and to further delineate the biological differences between
symptoms of apathy and mood enhancement in individuals with
MDD.
The overall safety and tolerability ﬁndings observed in these
studies are consistent with previously published studies of LDX
augmentation for MDD with other clinical studies of LDX for which
LDX is approved for use (Adler et al., 2008; Madhoo et al., 2014;
McElroy et al., 2016; Trivedi et al., 2013 Wigal et al., 2010). In-
somnia, dry mouth, headache, decreased appetite, and nasophar-
yngitis were among the most frequently reported TEAEs with LDX.
LDX was associated with greater mean increases in pulse rate and
blood pressure than placebo and with decreases in weight and
BMI.
These ﬁndings should be considered in light of several limita-
tions. First, these studies used remote telephone assessment of the
Table 3
Summary of safety and tolerability during double-blind treatment, safety analysis set.
Study 1 Study 2
Placebo (n¼201) LDX (n¼201) Placebo (n¼213) LDX (n¼211)
Any TEAE, n (%) 118 (58.7) 131 (65.2) Any TEAE, n (%) 108 (50.7) 139 (65.9)
Serious TEAEs 5 (2.5) 3 (1.5) Serious TEAEs 1 (0.5) 1 (0.5)
Severe TEAEsa 6 (3.0) 4 (2.0) Severe TEAEsa 3 (1.4) 7 (3.3)
Treatment-related TEAEs 56 (27.9) 75 (37.3) Treatment-related TEAEs 43 (20.2) 85 (40.3)
TEAEs leading to discontinuationb 7 (3.5) 8 (4.0) TEAEs leading to
discontinuationb
1 (0.5) 2 (0.9)
TEAEs reported by 45% of participants in either treatment group TEAEs reported by 45% of participants in either treatment group
Insomnia 15 (7.5) 19 (9.5) Headache 16 (7.5) 25 (11.8)
Dry mouth 6 (3.0) 19 (9.5) Dry mouth 6 (2.8) 25 (11.8)
Decreased appetite 8 (4.0) 15 (7.5) Nasopharyngitis 19 (8.9) 14 (6.6)
Headache 21 (10.4) 13 (6.5) Decreased appetite 5 (2.3) 13 (6.2)
Nausea 10 (5.0) 13 (6.5) Insomnia 7 (3.3) 11 (5.2)
Nasopharyngitis 4 (2.0) 11 (5.5) Hyperhidrosis 1 (0.5) 11 (5.2)
Dizziness 10 (5.0) 9 (4.5)
Changes (mean7SD) from augmentation baseline at week 16/EOS Changes (mean7SD) from augmentation baseline at week 16/EOS
Diastolic blood pressure, mmHgc 0.477.69 1.578.60 Diastolic blood pressure, mmHgc 0.176.55 2.677.17
Systolic blood pressure, mmHgc 0.4710.04 1.279.70 Systolic blood pressure, mmHgc 0.378.39 2.679.79
Pulse, bpmc 0.779.75 5.9710.64 Pulse, bpmc 0.578.31 5.2710.34
ECG heart rate, bpmd 0.378.84 6.1710.29 ECG heart rate, bpmd 0.578.01 5.2710.67
ECG QT duration, msd 1.8721.67 11.4723.57 ECG QT duration, msd 1.6719.80 10.7725.23
ECG QTcF, msd 0.8711.30 0.8712.80 ECG QTcF, msd 0.0712.27 1.7713.03
Weight, kgc 0.371.90 1.072.16 Weight, kgc 0.271.64 1.072.21
BMI, kg/m2c 0.170.67 0.470.77 BMI, kg/m2c 0.170.58 0.370.77
Potentially clinically important vital signs at 2 consecutive visits (of which 1 was the
last visit)c
Potentially clinically important vital signs at 2 consecutive visits (of which 1 was
the last visit)c
Systolic blood pressure
Z140 mmHgc
2 (1.0) 0 Systolic blood pressure
Z140 mmHgc
0 3 (1.4)
Diastolic blood pressure
Z90 mmHgc
2 (1.0) 0 Diastolic blood pressure
Z90 mmHgc
0 5 (2.4)
Pulse Z100 bpmc 0 0 Pulse Z100 bpmc 0 3 (1.4)
BMI¼body mass index; ECG¼electrocardiogram; EOS¼end of study; QTcF¼Fridericia's corrected QTC interval; TEAE¼treatment-emergent adverse event.
a Severe TEAEs: study 1 (placebo: gingivitis, wound infection, laceration, headache, insomnia, suicide attempt [n¼1 for all]; LDX: fatigue, appendicitis, migraine, syncope,
apathy [n¼1 for all]); study 2 (placebo: seasonal allergy, sleep disorder, suicidal ideation [n¼1 for all]; LDX: dental caries, dry mouth, dyspepsia, nasopharyngitis, anxiety,
insomnia, restlessness, hot ﬂush [n¼1 for all]).
b TEAEs leading to discontinuation: study 1 (placebo: diarrhea, disturbance in attention, liver function test abnormal, syncope, suicide attempt, major depression, and
rash [n¼1 for all]; LDX: accidental overdose, sedation, systolic blood pressure increased, liver function test abnormal, musculoskeletal pain, pain in extremity, syncope, self-
injurious behavior, and palpitations [n¼1 for all]); study 2 (placebo: suicidal ideation [n¼1]; LDX: headache and anxiety [both n¼1]).
c Study 1 (placebo, n¼200; LDX, n¼201); study 2 (placebo, n¼213; LDX, n¼209).
d Study 1 (placebo, n¼189; LDX, n¼189); study 2 (placebo, n¼202; LDX, n¼196).
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reduce the overall number of raters and the potential for varia-
bility across raters. As inter-rater reliability was not assessed in the
current studies, it is a limitation that variability across raters is
unknown. The use of telephone measures is a method now being
used in clinical trials to reduce bias (Kobak et al., 2008). Even
though it may offer less speciﬁcity and more variability than a
face-to-face clinical assessment, due in part to the inability to vi-
sually observe the participant, it is important to note that the
validity of using standardized central rating via telephone corre-
lates well with face-to-face interviews (Kobak et al., 2008) and
that site- and participant-rated secondary assessments were con-
sistent with the primary efﬁcacy assessment. In addition, as al-
luded to above, it is possible that psychostimulants provide di-
mensional efﬁcacy and that assessment of speciﬁc MADRS items or
clusters may have revealed effects of LDX that were not apparent
in the total score. However, a detailed assessment of MADRS do-
mains was not performed because the primary and key secondary
endpoints consistently failed in both studies, making such as-
sessments statistically inappropriate and unreliable. Also, partici-
pants in the current studies lacked diversity in terms of race (most
were White) and gender (most were female). Those with psy-
chiatric comorbidities (including ADHD) and/or active medical
disorders were excluded and executive functioning was not fully
examined in these studies. Therefore, these ﬁndings are limited to
a speciﬁc MDD population and do not extend to potential MDDsubtypes. It should also be noted that the treatment duration in
the current studies was relatively short. A longer duration anti-
depressant lead-in phase may have increased the number of par-
ticipants exhibiting antidepressant responses, and a longer dura-
tion double-blind treatment phase may have increased the mag-
nitude of LDX responses. Finally, clinical trials for MDD are sus-
ceptible to having high placebo responses (Walsh et al., 2002),
which could mask a potential therapeutic effect.
In conclusion, in the 2 largest, randomized clinical trials of
stimulant augmentation of antidepressant therapy completed to
date, LDX was not superior to placebo in reducing the depressive
symptoms of MDD in individuals with inadequate responses to
standard antidepressant monotherapy. Although these studies did
not show a treatment difference, the potential exists that stimu-
lant augmentation may be appropriate in subgroups of individuals
with MDD (eg, treatment-resistant MDD) or with a different sti-
mulant augmentation.Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi:10.1016/j.jad.2016.07.006.
C. Richards et al. / Journal of Affective Disorders 206 (2016) 151–160160References
Adler, L.A., Goodman, D.W., Kollins, S.H., Weisler, R.H., Krishnan, S., Zhang, Y., Bie-
derman, J., 303 Study Group, 2008. Double-blind, placebo-controlled study of
the efﬁcacy and safety of lisdexamfetamine dimesylate in adults with atten-
tion-deﬁcit/hyperactivity disorder. J. Clin. Psychiatry 69, 1364–1373.
Arroll, B., Macgillivray, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., Crombie, I.,
2005. Efﬁcacy and tolerability of tricyclic antidepressants and SSRIs compared
with placebo for treatment of depression in primary care: a meta-analysis. Ann.
Fam. Med. 3, 449–456.
Basia, B., Multidimensional Assessment of Fatigue. [Online]. Available from: 〈http://
www.son.washington.edu/research/maf/〉 (cited January 9, 2014).
Candy, M., Jones, L., Williams, R., Tookman, A., King, M., 2008. Psychostimulants for
depression. Cochrane Database Syst. Rev. CD006722.
Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., Wa-
tanabe, N., Nakagawa, A., Omori, I.M., McGuire, H., Tansella, M., Barbui, C., 2009.
Comparative efﬁcacy and acceptability of 12 new-generation antidepressants: a
multiple-treatments meta-analysis. Lancet 373, 746–758.
DeBattista, C., Doghramji, K., Menza, M.A., Rosenthal, M.H., Fieve, R.R., Modaﬁnil in
Depression Study Group, 2003. Adjunct modaﬁnil for the short-term treatment
of fatigue and sleepiness in patients with major depressive disorder: a pre-
liminary double-blind, placebo-controlled study. J. Clin. Psychiatry 64,
1057–1064.
Dunlop, B.W., Crits-Christoph, P., Evans, D.L., Hirschowitz, J., Solvason, H.B., Rickels,
K., Garlow, S.J., Gallop, R.J., Ninan, P.T., 2007. Coadministration of modaﬁnil and
a selective serotonin reuptake inhibitor from the initiation of treatment of
major depressive disorder with fatigue and sleepiness: a double-blind, placebo-
controlled study. J. Clin. Psychopharmacol. 27, 614–619.
Fava, M., Thase, M.E., DeBattista, C., Doghramji, K., Arora, S., Hughes, R.J., 2007.
Modaﬁnil augmentation of selective serotonin reuptake inhibitor therapy in
MDD partial responders with persistent fatigue and sleepiness. Ann. Clin.
Psychiatry 19, 153–159.
Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q.V., Pikalov, A.S., Thase, M.E.,
2009. A systematic review of augmentation strategies for patients with major
depressive disorder. Psychopharmacol. Bull. 42, 57–90.
Guy, W., 1976. Clinical Global Impressions. US Department of Health, Education, and
Welfare. Public Health Service, Alcohol, Drug Abuse and Mental Health Ad-
ministration. NIMH Psychopharmacology Research Branch, Rockville, MD.
Kaneda, Y., Keefe, R.S., 2015. An abbreviated version of the brief assessment of
cognition in schizophrenia (BACS). Eur. J. Psychiatry 29, 131–134.
Kobak, K.A., Williams, J.B., Jeglic, E., Salvucci, D., Sharp, I.R., 2008. Face-to-face
versus remote administration of the Montgomery-Asberg Depression Rating
Scale using videoconference and telephone. Depress. Anxiety 25, 913–919.
Kraemer, H.C., Kupfer, D.J., 2006. Size of treatment effects and their importance to
clinical research and practice. Biol. Psychiatry 59, 990–996.
Madhoo, M., Keefe, R.S., Roth, R.M., Sambunaris, A., Wu, J., Trivedi, M.H., Anderson,
C.S., Lasser, R., 2014. Lisdexamfetamine dimesylate augmentation in adults with
persistent executive dysfunction after partial or full remission of major de-
pressive disorder. Neuropsychopharmacology 39, 1388–1398.
McElroy, S.L., Hudson, J.I., Ferreira-Cornwell, M.C., Radewonuk, J., Whitaker, T.,
Gasior, M., 2016. Lisdexamfetamine dimesylate for adults with moderate to
severe binge eating disorder: results of two pivotal phase 3 randomized con-
trolled trials. Neuropsychopharmacology 41, 1251–1260 (In press).
McGregor, C., Srisurapanont, M., Mitchell, A., Longo, M.C., Cahill, S., White, J.M.,
2008. Psychometric evaluation of the amphetamine cessation symptom as-
sessment. J. Subst. Abus. Treat. 34, 443–449.
Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to besensitive to change. Br. J. Psychiatry 134, 382–389.
Patkar, A.A., Masand, P.S., Pae, C.U., Peindl, K., Hooper-Wood, C., Mannelli, P., Cic-
cone, P., 2006. A randomized, double-blind, placebo-controlled trial of aug-
mentation with an extended release formulation of methylphenidate in out-
patients with treatment-resistant depression. J. Clin. Psychopharmacol. 26,
653–656.
Posner, K., Brent, D., Lucas, C., Gould, M., Stanley, B., Brown, G., Fisher, P., Zelazny, J.,
Burke, A., Oquendo, M., Mann, J., 2009. Columbia-Suicide Severity Rating Scale.
[Online]. Available from: 〈http://www.cssrs.columbia.edu/scale_versions.html〉
(cited January 23, 2015).
Postolache, T.T., Rosenthal, R.N., Hellerstein, D.J., Aromin, R., Kelton, G.M., Muran, J.
C., Londono, J.H., 1999. Early augmentation of sertraline with methylphenidate.
J. Clin. Psychiatry 60, 123–124.
Ravindran, A.V., Kennedy, S.H., O’Donovan, M.C., Fallu, A., Camacho, F., Binder, C.E.,
2008. Osmotic-release oral system methylphenidate augmentation of anti-
depressant monotherapy in major depressive disorder: results of a double-
blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 69, 87-–94.
Robin, A.A., Wiseberg, S., 1958. A controlled trial of methyl phenidate (ritalin) in the
treatment of depressive states. J. Neurol. Neurosurg. Psychiatry 21, 55–57.
Rosenberg, P.B., Lanctot, K.L., Drye, L.T., Herrmann, N., Scherer, R.W., Bachman, D.L.,
Mintzer, J.E., ADMET Investigators, 2013. Safety and efﬁcacy of methylphenidate
for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J.
Clin. Psychiatry 74, 810–816.
Rush, A.J., Trivedi, M.H., Ibrahim, H.M., Carmody, T.J., Arnow, B., Klein, D.N., Mar-
kowitz, J.C., Ninan, P.T., Kornstein, S., Manber, R., Thase, M.E., Kocsis, J.H., Keller,
M.B., 2003. The 16-item Quick Inventory of Depressive Symptomatology (QIDS),
clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation
in patients with chronic major depression. Biol. Psychiatry 54, 573–583.
Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden,
D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Ro-
senbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., 2006. Acute and
longer-term outcomes in depressed outpatients requiring one or several
treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917.
Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A., 1996. The measurement of disability.
Int. Clin. Psychopharmacol. 11, 89–95.
Trivedi, M.H., Cutler, A.J., Richards, C., Lasser, R., Geibel, B.B., Gao, J., Sambunaris, A.,
Patkar, A.A., 2013. A randomized controlled trial of the efﬁcacy and safety of
lisdexamfetamine dimesylate as augmentation therapy in adults with residual
symptoms of major depressive disorder after treatment with escitalopram. J.
Clin. Psychiatry 74, 802–809.
Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., Ritz, L.,
Nierenberg, A.A., Lebowitz, B.D., Biggs, M.M., Luther, J.F., Shores-Wilson, K.,
Rush, A.J., 2006a. Medication augmentation after the failure of SSRIs for de-
pression. N. Engl. J. Med. 354, 1243–1252.
Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L.,
Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs,
M.M., Balasubramani, G.K., Fava, M., 2006b. Evaluation of outcomes with cita-
lopram for depression using measurement-based care in STAR*D: implications
for clinical practice. Am. J. Psychiatry 163, 28–40.
Vyvanses (lisdexamfetamine dimesylate), 2015. Shire US Inc. Wayne, PA.
Walsh, B.T., Seidman, S.N., Sysko, R., Gould, M., 2002. Placebo response in studies of
major depression: variable, substantial, and growing. JAMA 287, 1840–1847.
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., for the 316 Study Group,
2010. Randomized, double-blind, placebo-controlled, crossover study of the
efﬁcacy and safety of lisdexamfetamine dimesylate in adults with attention-
deﬁcit/hyperactivity disorder: novel ﬁndings using a simulated adult workplace
environment design. Behav. Brain Funct. 6, 34.
